Botanix presents at European Dermatology Conference

Key highlights

·        Botanix will be presenting at the 27th EADV Congress in Paris, France

·        Botanix will provide an update on its Phase 2 products and other pipeline products

·        Botanix will have the opportunity to engage with market leading global pharmaceuticals organisations and researchers

Philadelphia PA and Sydney Australia, 13th September 2018 -- Medical dermatology company Botanix Pharmaceuticals Limited (ASX: BOT, “Botanix” or the “Company”) is pleased to release an updated company presentation for the 27th Congress of the European Academy of Dermatology and Venerology (EADV Congress), held in Paris, France.

To read the ASX announcement, please click here

Have you seen our earlier videos?

Click here to visit our new YouTube page

Click here to watch an introduction to Botanix Pharmaceuticals

Click here to watch the BTX 1204 Presentation

Click here to watch an interview with CMO, Dr Stephane Levy

For more information, please visit or follow us on Twitter @BotanixPharma

General Enquiries
Matt Callahan
Botanix Pharmaceuticals
Executive Director
P: +1 215 767 4184

Investor Enquiries
Joel Seah
Vesparum Capital
P: +61 3 8582 4800

Media Enquiries
Julia Maguire
The Capital Network
P: +61 419 815 386

Back to news